Postdoc researcher, at Fudan University, China.
Dr. Faiz Ali Khan, Ph.D., is an accomplished scientist in cell and molecular biology with over 10 years of research experience in cancer biology, genetics, and RNA-mediated regulation. Currently serving as a Postdoctoral Researcher at Fudan University, China, he previously worked at Shaukat Khanum Memorial Cancer Hospital and Research Center in Pakistan, where he led impactful research on tumor suppressor genes, oncogenes, and RNA modifications. Dr. Khan is known for integrating advanced molecular biology techniques with clinical applications, particularly in cancer therapeutics. His work has contributed to the understanding of cancer progression mechanisms and molecular markers. He possesses strong expertise in RNA-protein interactions, gene expression regulation, and proteomics, and collaborates internationally. He is driven by the goal of translating scientific discoveries into diagnostic and therapeutic breakthroughs. With multiple peer-reviewed publications, international fellowships, and prestigious awards, Dr. Khan is a recognized voice in the field of molecular oncology.
Professional Profile
Scopus
ORCID
Google Scholar
🎓 Education
Dr. Faiz Ali Khan holds a Ph.D. in Biochemistry & Molecular Biology from Henan University, China (2019–2023), supported by the Chinese Government Doctoral Scholarship. His doctoral research focused on the role of RNA-binding proteins and mRNA degradation in cancer progression. Prior to this, he earned an M.Phil. (2011) and M.Sc. (2008) in Genetics from Hazara University, Pakistan, where he explored genetic polymorphisms and cancer susceptibility. His academic journey began with a B.Sc. in Biology from the University of Malakand (2005), where he cultivated a passion for understanding genetic mechanisms. Throughout his education, Dr. Khan has demonstrated excellence in both coursework and laboratory research, receiving recognition for his dedication and academic contributions. His cross-disciplinary foundation bridges genetics, molecular biology, and biotechnology, equipping him with robust capabilities to tackle biomedical challenges. His research training spans across Asia, offering a global perspective on translational medicine and life science innovation.
🧪 Experience
Dr. Faiz Ali Khan currently works as a Postdoctoral Researcher at the Institute of Integrative Medicine, Fudan University, Shanghai, where he studies oncogene modulation and RNA dynamics in tumor cells. From 2013 to 2018, he was a Research Associate at the Basic Science Research Lab of Shaukat Khanum Memorial Cancer Hospital, Lahore, a premier oncology institute. There, he led numerous projects involving molecular genetics, cellular assays, and xenograft models, focusing on breast and esophageal cancers. Earlier, he served as a Research Fellow (2011–2012) in the same institution, gaining hands-on experience in genetic screening, transfection techniques, and epigenetic profiling. His technical expertise includes RNA-IP, ChIP, Western blotting, flow cytometry, DHPLC, and more. Dr. Khan has also mentored junior researchers and collaborated on large-scale genomics studies. His extensive background in laboratory research and clinical correlation has greatly contributed to advancing cancer molecular diagnostics and precision medicine.
🔬 Research Interests
Dr. Faiz Ali Khan’s research interests revolve around the molecular mechanisms underlying cancer progression, especially the roles of RNA-binding proteins (e.g., FXR1), epigenetic modulators, and RNA methylation (m6A). He investigates how non-coding RNAs, pseudogenes, and circRNAs influence gene expression, chromatin remodeling, and tumorigenesis. His work also focuses on understanding the dynamics of oncogene and tumor suppressor gene regulation, utilizing tools like RNA immunoprecipitation, ChIRP, and real-time PCR. Dr. Khan is particularly interested in translating basic science findings into potential therapeutic targets, such as identifying phytochemicals (e.g., Icariside II) for treating asthma and cancer. Additionally, he explores liquid phase separation in epigenetics, protein-protein interactions, and molecular markers for early cancer detection. His interdisciplinary approach combines biochemistry, proteomics, and genomics to advance personalized medicine. By bridging lab-based experiments with clinical relevance, Dr. Khan contributes meaningfully to biomedical innovation and cancer treatment strategies.
🏆 Awards
Dr. Faiz Ali Khan has been recognized for his scientific excellence and research contributions throughout his career. In 2024, he was appointed as a Postdoctoral Researcher at Fudan University, supported by China’s prestigious Doctoral Talent Program. His Ph.D. at Henan University (2018–2023) was fully funded by the Chinese Government Doctoral Scholarship, a competitive international award. In 2017, Dr. Khan was honored with the Employee of the Year Award at Shaukat Khanum Memorial Cancer Hospital, acknowledging his dedication to cancer research and team leadership. Additionally, he has received multiple nominations for his contributions to translational oncology and molecular diagnostics. Dr. Khan’s accolades reflect his commitment to innovation, ability to manage complex projects, and contribution to global cancer research initiatives. These achievements underscore his reputation as a leading young scientist in the fields of genetics, molecular biology, and oncology.
📚Top Noted Publications
Dr. Faiz Ali Khan has authored numerous high-impact publications across oncology, molecular biology, and genetics:
1. FXR1 and Esophageal Cancer Progression
2. MRPS23 in Breast Cancer
-
Authors: [Author details not available]
-
Journal: Cellular and Molecular Biology
-
Year: 2024
-
Citation Count: 6
-
DOI: [DOI not available]
3. m6A Methylation and Diseases
-
Authors: [Author details not available]
-
Journal: Cancer Gene Therapy
-
Year: 2024
-
Citation Count: 9
-
DOI: [DOI not available]PubMed CentralPubMed Central+5Frontiers+5Frontiers+5SpringerLink
4. FXR1P in Cancer: A Review
-
Authors: [Author details not available]
-
Journal: Cell Death & Disease
-
Year: 2024
-
Citation Count: 14
-
DOI: [DOI not available]
5. FANCM Variants in Breast/Ovarian Cancer
-
Authors: Rashid MU, Muhammad N, Shehzad U, et al.
-
Journal: Familial Cancer
-
Year: 2023
-
Citation Count: 5
-
DOI: 10.1007/s10689-022-00304-1SpringerLinkPubMed Central+1NCBI+1
6. circRNAs in Cancer
-
Authors: [Author details not available]
-
Journal: Gene and Protein Disease
-
Year: 2022
-
Citation Count: 4
-
DOI: [DOI not available]PubMed CentralSpringerLink
7. Pseudogenes in Epigenetics
-
Authors: [Author details not available]
-
Journal: Frontiers in Oncology
-
Year: 2022
-
Citation Count: 10
-
DOI: [DOI not available]
8. circRNA-Encoded Proteins
-
Authors: [Author details not available]
-
Journal: Frontiers in Oncology
-
Year: 2022
-
Citation Count: 11
-
DOI: [DOI not available]
9. Processing Body in Cancer
-
Authors: [Author details not available]
-
Journal: Molecular and Cellular Biochemistry
-
Year: 2022
-
Citation Count: 7
-
DOI: [DOI not available]PubMed CentralFrontiers+3Frontiers+3Frontiers+3
10. Vitamin D Polymorphism and Breast Cancer
Conclusion
Dr. Faiz Ali Khan is highly suitable for the Research for Molecular Biology Contribution Award. His technical depth, publication record, and innovative contributions to cancer molecular biology firmly position him as a strong candidate. With minor enhancements in visibility and leadership narratives, his profile could match or surpass international standards for such honors.